Kinnate Biopharma Inc.

Equities

KNTE

US49705R1059

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 16:00:00 2024-04-02 EDT			5-day change	1st Jan Change
2.65 ^USD	-0.38%		-.--%	+11.81%

04-03	Kinnate Biopharma Inc. Announces Board Resignations	CI
04-03	Kinnate Biopharma Inc.(NasdaqGS:KNTE) dropped from NASDAQ Composite Index	CI

Kinnate Biopharma Inc. Appoints Helen Sabzevari to Board of Directors

June 28, 2021 at 11:05 am

Kinnate Biopharma Inc. announced the appointment of Helen Sabzevari, Ph.D. to its Board of Directors. Dr. Sabzevari is a global thought leader who is internationally recognized for her work in the field of oncology. Dr. Sabzevari is currently President and CEO of Precigen Inc., a dedicated discovery and clinical stage biopharmaceutical company.

Latest news about Kinnate Biopharma Inc.

Kinnate Biopharma Inc. Announces Board Resignations	04-03	CI
Kinnate Biopharma Inc.(NasdaqGS:KNTE) dropped from NASDAQ Composite Index	04-02	CI
XOMA Corporation completed the acquisition of Kinnate Biopharma Inc..	04-02	CI
Kinnate Biopharma Inc.(NasdaqGS:KNTE) dropped from S&P TMI Index	04-02	CI
North American Morning Briefing : Stocks Seen -2-	04-02	DJ
Kinnate Biopharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
North American Morning Briefing : Markets Steady -2-	03-26	DJ
Kinnate Biopharma Sells Cancer Treatment Assets to Pierre Fabre Laboratories	03-01	MT
Stifel Raises Kinnate Biopharma's Price Target to $2.59 From $1.50, Keeps Hold Rating	02-26	MT
Sector Update: Health Care Stocks Advance Friday Afternoon	02-16	MT
Wedbush Adjusts Kinnate Biopharma's PT to $2.34 From $2 on Heels of Announced Sale Agreement With XOMA, Keeps Neutral Rating	02-16	MT
XOMA Agrees to Acquire Kinnate Biopharma	02-16	MT
XOMA Corporation entered into a definitive merger agreement to acquire Kinnate Biopharma Inc. for approximately $120 million.	02-15	CI
Kinnate Biopharma Plans to Further Reduce Workforce by 56%	01-17	MT
Kinnate Biopharma Inc.(NasdaqGS:KNTE) dropped from NASDAQ Biotechnology Index	12-15	CI
Sector Update: Health Care Stocks Mixed Late Afternoon	11-15	MT
Top Midday Gainers	11-15	MT
Top Premarket Gainers	11-15	MT
Kinnate Biopharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
North American Morning Briefing : Fed Seen Holding -2-	23-09-20	DJ
Jefferies Cuts Price Target on Kinnate Biopharma to $2 From $31, Maintains Buy Rating	23-09-19	MT
Sector Update: Health Care Stocks Mixed Premarket Tuesday	23-09-19	MT
Sector Update: Health Care	23-09-19	MT
HC Wainwright Downgrades Kinnate Biopharma to Neutral From Buy	23-09-19	MT
Wedbush Downgrades Kinnate Biopharma to Neutral From Outperform After News of Restructuring, Workforce Reduction; Cuts PT to $2 From $14	23-09-19	MT

Chart Kinnate Biopharma Inc.

Duration

Period

More charts

Company Profile

Kinnate Biopharma Inc. is a clinical-stage precision oncology company. The Company is focused on the discovery, design, and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers. The Companyâs product candidate is KIN-3248, a Fibroblast Growth Factor Receptors (FGFR) inhibitor which was designed for the treatment of patients with intrahepatic cholangiocarcinoma (ICC), a cancer of the bile ducts in the liver, and urothelial carcinoma (UC), a cancer of the bladder lining, as well as other solid tumors. Its early-stage programs include a c-MET inhibitor that targets resistant variants and a brain penetrant CDK4 selective program. The Company concentrates its efforts on addressing known oncogenic drivers for targeted therapies and to overcome the limitations associated with existing cancer therapies, such as non-responsiveness or the development of acquired and intrinsic resistance.

Sector

Biotechnology & Medical Research

Calendar

2024-08-06 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
KINNATE BIOPHARMA INC.	+11.81%	125M
MODERNA, INC.	+64.92%	62.59B
IQVIA HOLDINGS INC.	-1.85%	41.18B
LONZA GROUP AG	+44.76%	40.29B
CELLTRION, INC.	-8.93%	27.9B
ICON PUBLIC LIMITED COMPANY	+13.05%	26.21B
ALNYLAM PHARMACEUTICALS, INC.	-21.96%	19.09B
BIO-TECHNE CORPORATION	+4.21%	13.08B
UNITED THERAPEUTICS CORPORATION	+25.74%	12.26B
MEDPACE HOLDINGS, INC.	+27.42%	12.05B

Other Biotechnology & Medical Research